Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer

Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe

Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies

Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor

Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China

Enveda launches Phase 1 trial for first-in-class Oral IBD therapy

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers

UK to get groundbreaking early detection test for bowel cancer

Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status

Zydus signs exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India

GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate